BeyondSpring Inc. Ordinary Shares - BYSI STOCK NEWS

BeyondSpring, a biopharmaceutical company, filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the SEC on April 30, 2021. The report includes audited financial statements and is accessible via the SEC's website and BeyondSpring's site under the Investors section. BeyondSpring focuses on developing innovative cancer therapies, primarily its lead asset plinabulin, aimed at preventing chemotherapy-induced neutropenia and studying its effects in non-small cell lung cancer. Shareholders can request a hard copy of the report free of charge.

BeyondSpring, a biopharmaceutical company focused on innovative cancer therapies, reported its 2020 financial results and recent milestones. The company completed NDAs for plinabulin in the U.S. and China for preventing chemotherapy-induced neutropenia, leveraging positive Phase 3 trial data. BeyondSpring secured $86.3 million in equity financing, ending 2020 with $109.5 million in cash. R&D expenses rose to $41.8 million while G&A expenses increased to $22.6 million, leading to a net loss of $61 million. Positive Phase 3 survival data for NSCLC is anticipated in mid-2021.

BeyondSpring (NASDAQ: BYSI) has announced five key presentations at the ASCO Annual Meeting, focusing on plinabulin, its lead cancer therapy. The presentations will highlight clinically significant improvements, including the reduction of febrile neutropenia and hospitalization rates in patients undergoing chemotherapy. Notably, plinabulin's combination with checkpoint inhibitors targeting small cell lung cancer will also be discussed. BeyondSpring aims to demonstrate plinabulin's unique capabilities in enhancing patient outcomes as it seeks to bring the drug to market in 2022.

BeyondSpring Inc. (NASDAQ: BYSI) will report its financial results for the year and quarter ending December 31, 2020, on April 30, 2021. A conference call is scheduled for 8:30 AM ET on the same day to discuss these results and provide a corporate update. BeyondSpring focuses on developing innovative cancer therapies, with its lead asset, plinabulin, aimed at preventing chemotherapy-induced neutropenia and currently under NDA review in the US and China. The company also has a pivotal study in non-small cell lung cancer and various immuno-oncology assets in its pipeline.

BeyondSpring has submitted a New Drug Application (NDA) to the FDA and China NMPA for plinabulin in combination with G-CSF to prevent chemotherapy-induced neutropenia (CIN). This innovative approach addresses a significant unmet medical need, as CIN represents a major complication in cancer treatment. The PROTECTIVE-2 Phase 3 study showed that plinabulin plus G-CSF improved grade 4 neutropenia prevention from 13.6% to 31.5%. The NDA is supported by data from five trials involving over 1,200 patients, indicating potential to enhance patient care and outcomes in oncology.

BeyondSpring (BYSI) announced a KOL webinar on March 18, 2021, focusing on Plinabulin, its lead asset aimed at preventing chemotherapy-induced neutropenia (CIN). Experts Douglas Blayney and Jeffrey Vacirca will present, detailing the unmet medical needs in CIN prevention. The update includes recent progression in Plinabulin's clinical trials, with positive topline data from the PROTECTIVE-2 Phase 3 trial. Currently, Plinabulin is also in the DUBLIN-3 trial for non-small cell lung cancer, with results expected in H2 2021, highlighting its potential dual functionality in oncology.

BeyondSpring, a biopharmaceutical company focused on innovative cancer therapies, announced CEO Dr. Lan Huang's virtual presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 7:30 a.m. ET. The company will also hold one-on-one meetings during the LifeSci Advisors Corporate Access Event from January 7-13, 2021. BeyondSpring's lead asset, plinabulin, is in Phase 3 trials for non-small cell lung cancer and is recognized by the U.S. FDA as a Breakthrough Therapy for preventing chemotherapy-induced neutropenia.

BeyondSpring (NASDAQ: BYSI) announced that CEO Dr. Lan Huang will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 7:30 a.m. ET. The leadership team will also be available for one-on-one meetings during the LifeSci Advisors Corporate Access Event on January 7-8 and 11-13, 2021. BeyondSpring focuses on developing innovative cancer therapies, including plinabulin, which received Breakthrough Therapy designation from the U.S. FDA. More details can be found in the Events and Presentations section of the BeyondSpring website.

BeyondSpring (NASDAQ: BYSI) announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors, aiming to strengthen its oncology expertise as it seeks commercial approval for plinabulin. This follows promising Phase 3 data from the PROTECTIVE-2 study, which evaluates the drug's efficacy in preventing chemotherapy-induced neutropenia. Dr. Vacirca brings extensive experience as CEO of New York Cancer & Blood Specialists and is well-regarded in the oncology community, expected to enhance collaboration and strategic direction for BeyondSpring.